Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|December 1, 2000
Supplements and Featured Publications
- The Latest Clinical Advances in Antimicrobial Use -- A Managed Care Perspective
- Volume 6
- Issue 23 Suppl
Guidelines for the Management of Community-Acquired Pneumonia
Author(s)Richard E. Chaisson, MD
Advertisement
Articles in this issue
almost 26 years ago
Participating Facultyalmost 26 years ago
Introductionalmost 26 years ago
Clinical Choices of Antibiotics: Judging Judicious Usealmost 26 years ago
Is Drug Resistance Affecting Treatment Outcomes?almost 26 years ago
Optimizing the Use of Antimicrobial Therapyalmost 26 years ago
Selected Abstractsalmost 26 years ago
Continuing Medical Education QuizAdvertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Extension Studies in TPIP Show Promise in PAH, PH-ILD
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5